Nasus Pharma Ltd. NSRX
3.48
0.00
0.00%
as of 25 Sep
- Market cap
- $40.8M
- P/E
- —
Follow NSRX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow |
— | — | (7.04) | (12.07) | |
Capital Expenditures |
— | — | — | (0.02) | |
Piotroski F-Score |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | (173.56%) | (63.77%) | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | 0.00 | 0.00 | |
Depreciation/Fixed assets |
— | — | — | 0.00 | |
Capex/Depreciation |
— | — | — | 0.00 | |
Operating CF per Share |
— | — | 0.00 | 0.00 | |
Capex per Share |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates